New India plant lifts Shasun's earnings; WTO may referee fight on Europe's API import rule;

> A $19 million investment in an API plant in Vizag, India, has helped Shasun Pharmaceuticals more than double its earnings in the last quarter. Story

> Swiss drugmaker Acino opened a new plant for transdermal therapeutic systems at the company's site in Miesbach, Germany. Release

> The FDA has OK'd a manufacturing change that will allow ViroPharma to scale up production of its injectable drug for hereditary angioedema, which causes swelling under the skin. Story

> India intends to set up pharmaceutical manufacturing in Sri Lanka as part of an effort to strengthen trade between the two countries. Story

> China and India may file a World Trade Organization complaint over the European Commission's pending rule that exporting countries must certify that APIs meet EC standards. Story

> Mylan ($MYL) says a subsidiary has started manufacturing 18 anti-retroviral products in India. Story

> And Finally... NPS Pharmaceuticals believes that its contract manufacturer will quickly resolve fill-and-finish issues that are keeping it from producing the drug to specifications so the company can submit its biologics license application for the bioengineered hormone Natpara by year's end. Story

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.